Expert Panel Updates PAH Therapy Guidelines

2019-02-21T21:44:57+00:00 February 21st, 2019|

Updated guidelines for pulmonary arterial hypertension (PAH) were recently completed by a panel of experts from the Pulmonary Hypertension Association, American Thoracic Society and the American Heart Association and published in the CHEST Journal. The panel, which included several PHA members and a patient representative, looked at 300 recent studies to complete the update

Advances in Pulmonary Hypertension Looks at Different Approaches to Treat Pediatric PH

2019-02-07T19:29:29+00:00 February 7th, 2019|

Although the World Symposium on Pulmonary Hypertension (WSPH) has led pulmonary hypertension (PH) to be considered in five classifications, or groups, pediatric PH is more nuanced and there is increasing recognition of unique genotypic and phenotypic subsets of the disease. This necessitates individualized and precision approaches to treatments for children with PH that will

PHA’s Online Advances in Pulmonary Hypertension Examines Barriers in New PH Therapies

2019-01-31T20:19:28+00:00 January 31st, 2019|

The latest issue of Advances in Pulmonary Hypertension: Official Journal of the Pulmonary Hypertension Association (PHA) — a free quarterly publication directed by an editorial board of renowned pulmonary hypertension (PH) experts — includes an article by Brian Graham, M.D., Peter Fernandes, M. Pharm., and Sue Gu, M.D., that explores the barriers and solutions to

Early Signs of Pulmonary Vascular Disease Found in Adults Born Prematurely

2019-01-24T22:05:08+00:00 January 24th, 2019|

One in 10 people in the U.S. is born prematurely. Premature birth is known to be associated with pulmonary vascular disease in infants and children, and registry studies have found those born prematurely are three to five times more likely to develop pulmonary hypertension (PH) as adolescents or young adults. Less is known, however,

Data Collected Through PHA’s Research Room Leads to the Identification of PAH Biomarker

2019-01-10T22:26:08+00:00 January 10th, 2019|

Since the first Pulmonary Hypertension Association (PHA) Conference in 1994, the Research Room at PHA’s International PH Conference and Scientific Sessions has offered a dedicated space for individuals with pulmonary hypertension (PH) and their families to participate in research by leading physicians and scientists. This participation furthers the researchers’ studies through the collection of

Is Race a Risk Factor for Pulmonary Hypertension?

2018-12-13T18:27:13+00:00 December 13th, 2018|

by Phyllis Hanlon, Contributing Writer Few studies have examined whether race makes a difference in how often pulmonary hypertension (PH) occurs and what causes it. These questions prompted a specialist team at Vanderbilt University Medical Center, an accredited Pulmonary Hypertension Care Center (PHCC), to explore the issue. Overall, the team found that the African

Researchers at Vanderbilt Publish First Study from PHA’s 2018 Research Room

2018-11-29T21:44:15+00:00 November 29th, 2018|

Using fitness devices and cell phones, pulmonary hypertension (PH) researchers compared the physical activity of individuals with and without pulmonary arterial hypertension (PAH) in the first research study published using data collected through the Research Room at the Pulmonary Hypertension Association’s (PHA’s) 2018 International PH Conference and Scientific Sessions in Orlando, Fla. By collecting

Common Antacids: Beneficial for Patients with Pulmonary Hypertension?

2018-11-16T23:15:42+00:00 November 16th, 2018|

by Phyllis Hanlon, Contributing Writer Certain over-the-counter (OTC) medications such as Pepcid®, Tagamet® and Zantac® are used to treat ulcers and excess stomach acid. These drugs, technically known as histamine-2 (H2) receptor antagonists, suppress stomach acid, which can be caused by certain foods, caffeine, allergens, insulin and other substances. A recent analysis shows these common

PAH Study: Is Morbidity Related to Mortality?

2018-11-09T22:34:24+00:00 November 9th, 2018|

by Phyllis Hanlon, Contributing Writer People with a serious illness such as pulmonary hypertension (PH) must form a partnership with their health care providers to effectively manage the disease in a way that enhances quality of life. Two recent clinical trials related to World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or

PH with COPD: Is Sildenafil an Effective Treatment Option?

2018-10-26T20:46:19+00:00 October 26th, 2018|

by Phyllis Hanlon, Contributing Writer All of the 14 targeted therapies for pulmonary hypertension (PH) are approved for use in patients with World Health Organization (WHO) Group 1 PH (pulmonary arterial hypertension, or PAH), with one therapy also approved for use in patients with inoperable or recurrent WHO Group 4 PH (chronic thromboembolic pulmonary hypertension,